vimarsana.com

Page 10 - ரோசாலிண்ட் பிராங்க்ளின் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How UChicago s vaccine rollout put equity first • AbbVie could sell off women s drug portfolio • Chicago begins vaccinating the homeless

How UChicago s vaccine rollout put equity first • AbbVie could sell off women s drug portfolio • Chicago vaccinating the homeless March 17, 2021 05:15 AM How UChicago s vaccine rollout put equity first • AbbVie could sell off women s drug portfolio • Chicago vaccinating the homeless Crain s Health Pulse is your source for actionable, exclusive and inside news on the health care industry. Curbside COVID-19 testing at the University of Chicago Medicine campus. HOW UCHICAGO S VACCINE ROLLOUT PUT EQUITY FIRST: The rollout of COVID-19 vaccines across the country was fraught with potential ethical quandaries and concerns over how, and if, health providers would reach the neighborhoods most at risk mainly Black and Latino communities still haven’t subsided.

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

Press release content from Accesswire. The AP news staff was not involved in its creation. 9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update March 15, 2021 GMT Tuesday, March 23rd @ 11am Eastern Time RALEIGH, NC / ACCESSWIRE / March 15, 2021 / 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that it will host a key opinion leader (KOL) webinar on short bowel syndrome (SBS) and provide an update on the NM-002 (proprietary GLP-1 agonist) development program on Tuesday, March 23, 2021 at 11am Eastern Time. The webinar will feature presentations by KOLs Carol Rees Parrish, M.S., R.D.N., University of Virginia Health, and 9 Meter’s management who will discuss the current development status of NM-002. Additional topics will include the following:

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.